LAG3 and acute myeloid leukemia: Analysis of the co-expression of LAG-3, TIM-3 and PD-1 in AML patients and healthy donors showed that those patients with longer survival times had a higher percentage of LAG-3+ TIM-3+ PD-1− NK cells and T cells than those with lower survival and that this percentage was similar to that observed in healthy donors (Fig. 8).